Apelin, a novel peptide originally isolated from bovine stomach tissue extracts, is widely but selectively distributed throughout the nervous system. Vasopressin and oxytocin are synthesized in the magnocellular neurons of the hypothalamic supraoptic nucleus (SON) and paraventricular nucleus, which are apelin-rich regions in the central nervous system. We made extracellular electrophysiological recordings from the transpharyngeally exposed SON of urethane-anaesthetized rats to assess the role of apelin in the control of the firing activity of identified magnocellular vasopressin and oxytocin neurons in vivo. Apelin-13 administration onto SON neurons via microdialysis revealed cell-specific responses; apelin-13 increased the firing rates of vasopressin cells but had no effect on the firing rate of oxytocin neurons. A direct excitatory effect of apelin-13 on vasopressin cell activity is also supported by our in vitro studies showing depolarization of membrane potential and increase in action potential firing. To assess the effects of apelin-13 on somatodendritic peptide release, we used in vitro release studies from SON explants in combination with highly sensitive and specific RIA. Apelin-13 decreases basal (by 78%; P < 0.05; n ‫؍‬ 6) and potassium-stimulated (by 57%; P < 0.05; n ‫؍‬ 6) vasopressin release but had no effect on somatodendritic oxytocin release. Taken together, our data suggest a local autocrine feedback action of apelin on magnocellular vasopressin neurons. Furthermore, these data show a marked dissociation between axonal and dendritic vasopressin release with a decrease in somatodendritic release but an increase in electrical activity at the cell bodies, indicating that release from these two compartments can be regulated wholly independently. (Endocrinology 149: 6136 -6145, 2008) I MMUNOHISTOCHEMICAL and in situ hybridization studies have shown that apelin, a peptide originally isolated from bovine stomach tissue extracts (1), is widely distributed throughout the body as well the central nervous system (2-8). Apelin is derived from a 77-amino-acid precursor, pre-pro-apelin, which is processed to several different forms in different tissues (4, 7). Those reported to have the highest in vitro activity on the G protein-coupled, seventransmembrane domain apelin receptor (APJ) are apelin-13 and apelin-17 (3, 9). The highly conserved structure of apelin and its receptor between species has prompted suggestions of important physiological functions for apelin, and so far, roles in pressure/volume homeostasis, modulating pituitary hormone release, food and water intake, and stress and immune system activation have been described (reviewed in Refs. 10 -17).
I MMUNOHISTOCHEMICAL and in situ hybridization
studies have shown that apelin, a peptide originally isolated from bovine stomach tissue extracts (1) , is widely distributed throughout the body as well the central nervous system (2) (3) (4) (5) (6) (7) (8) . Apelin is derived from a 77-amino-acid precursor, pre-pro-apelin, which is processed to several different forms in different tissues (4, 7) . Those reported to have the highest in vitro activity on the G protein-coupled, seventransmembrane domain apelin receptor (APJ) are apelin-13 and apelin-17 (3, 9). The highly conserved structure of apelin and its receptor between species has prompted suggestions of important physiological functions for apelin, and so far, roles in pressure/volume homeostasis, modulating pituitary hormone release, food and water intake, and stress and immune system activation have been described (reviewed in Refs. 10 -17).
Like APJ, apelin is found in a variety of brain areas including hippocampus, cerebellum, striatum, and hypothalamus (4 -6, 8, 11, 18, 19) . Some of the most apelin-rich regions in the brain, with a dense network of apelin-immunoreactive nerve cell bodies, dendrites, and axons, are the vasopressinand oxytocin-synthesizing magnocellular neurons of the supraoptic nucleus (SON) and paraventricular nucleus (PVN) of the hypothalamus (9, 20). The neuropeptides are released from axon terminals in the neural lobe of the pituitary and from somata and dendrites within the hypothalamus. Vasopressin and oxytocin secretion from the pituitary into the general circulation plays a considerable role in the physiological regulation of fluid homeostasis and reproduction. Oxytocin and vasopressin released from dendrites act as retrograde signals that modulate synaptic transmission, electrical activity, and in some cases, morphology of the cell of origin (reviewed in Refs. 21, 22).
Initially, a subpopulation of apelin-immunoreactive magnocellular neurons were shown to be oxytocinergic, as indicated by their signal for neurophysin I (9). However, a recent paper has shown that almost all apelin-immunoreactive cells are immunopositive for vasopressin, although the apelin-immunoreactive cells represented only a small subset of vasopressin neurons. Although both were found in the cytoplasm, the apelin and vasopressin signals were not colocalized within the neurons. Moreover, a 48-h dehydration stimulus applied in vivo depleted the somatodendritic vasopressin signal although resulting in an increased apelin signal in both the number of apelin-positive cells as well as labeling density, suggesting that the two peptides might be stored in, and therefore differentially released from, two distinct vesicular pools within the same cells (23). In addition to apelin, APJ mRNA is expressed in magnocellular neurons (3, 18) , suggesting a local role of apelin/APJ in regulating vasopressin neurons.
However, contrasting effects of apelin in regulating vasopressin release and drinking behavior have been reported. Intracerebroventricular (icv) injection of apelin-17 decreased the electrical activity of vasopressin cells in lactating animals (24). The icv injection of apelin-13 or -17 inhibited basal and dehydration-induced release of vasopressin and water intake in mice and rats (18), suggesting an inhibitory role of apelin in the regulation of vasopressin release. Two other studies observed regulatory actions of apelin on fluid homeostasis; apelin-13 administered icv dose-dependently increased water intake (5, 25) or had no effect on water intake in sated or water-deprived rats (26). Therefore, the aim of this study was to determine the direct effects of apelin-13 on the electrical activity and somatodendritic peptide release of vasopressin and oxytocin neurons.
Materials and Methods Animals
Sprague Dawley control (Bantin & Kingman, Hull, UK) or Wistar rats expressing a vasopressin-enhanced green fluorescent protein (vasopressin-eGFP) (27-29) were used in accordance with the United Kingdom Animals (Scientific Procedures) Act, 1996. Experiments conducted in Japan were in accordance with guidelines on the use and care of laboratory animals as set out by the Physiological Society of Japan and was approved by the Ethics Committee of Animal Care and Experiments of the University of Occupational and Environmental Health, Kitakyushu, Japan. Only the minimum number of rats necessary to produce reliable scientific data was used. All rats were housed under controlled conditions (12 h light, 12 h dark, 21 C) with free access to food and water.
Immunocytochemistry
Adult (250 -300 g) random cycling female Sprague Dawley rats were deeply anesthetized (Sagatal, 0.6 ml, ip) and then perfused through the ascending aorta first with heparin (5000 U/ml; 300 ml) in 0.9% saline solution followed by 300 ml of a 4% paraformaldehyde in 0.1 m phosphate buffer (PB, pH 7.4). The brain and pituitary were carefully removed and immersed overnight in a solution of 2% paraformaldehyde and 15% sucrose in 0.1 m PB at 4 C. The tissue was then placed in a solution of 30% sucrose in 0.1 m PB and left at 4 C until the tissue had sunk (usually 48 h). Tissue sections (40 m) were cut with a freezing microtome and rinsed in 0.1 m PB. Sections were first incubated for 30 min at room temperature in a blocking buffer consisting of 1% BSA plus 0.2% Triton X-100 in 0.1 m PB. Sections were incubated for 60 min at room temperature and then 48 h at 4 C with primary antibodies against APJ (rabbit polyclonal, diluted 1:50) (Santa Cruz Biotechnology, Santa Cruz, CA) (30), plus glial fibrillary acidic protein (GFAP, mouse monoclonal; diluted 1:200) (Imgenex Corp., San Diego, CA), or oxytocin (neurophysin-oxytocin PS38, mouse monoclonal, diluted 1:5000) or vasopressin (neurophysinvasopressin PS41 mouse monoclonal; diluted 1:5000). The vasopressin and oxytocin antibodies were a kind gift of Professor H. Gainer. 
In vivo electrophysiology
Female Sprague Dawley rats were anesthetized with an ip injection of urethane (1.25 g/kg); a femoral vein and the trachea were cannulated and the pituitary stalk and right SON were exposed transpharyngeally as described previously (31). In some animals, an additional icv cannula was implanted. A home-made U-shaped dialysis probe (molecular cutoff 6000 Da, Spectra/Por RC Hollow Fibers; Spectrum Medical Inc., Cartersville, GA) was bent to position the loop of the membrane flat onto the exposed ventral glial lamina of the SON after removal of the meninges (32 2 ) was dialyzed at 3 l/min throughout the experiment. During recording, dialysis fluid was changed to aCSF containing apelin-13 fragment (1 g/l) for 30 min. Drugs administered by microdialysis in this way penetrate only a short distance into the brain; the concentrations achieved 0.5-1 mm below the surface of the brain are about three to four orders of magnitude below the dialysate concentration over this duration of infusion (32). In some animals, apelin-13 was given icv at a dose of 0.1 g/2 l. At the end of each experiment, the rats were killed by overdose of pentobarbitone anesthetic (60 mg/kg, iv). The firing rates of cells were recorded using Spike2 software (Cambridge Electronic Design, Cambridge, UK) and interfaced to a personal computer. The mean firing rate (spikes per second) and the activity quotient (proportion of time in which a cell is active) were analyzed for 10-min intervals before, during, and after drug treatment.
In vitro electrophysiology
Recordings of apelin-induced currents were made in magnocellular neurons from isolated neuron and brain slice preparations. Neurons were isolated as previously described (34) Recordings were also made in 250-m hypothalamic slices containing SON neurons. The slices were prepared as above, without enzyme treatment, from wild-type Sprague Dawley rats as well as vasopressineGFP rats. Slices were allowed to rest for at least 60 min in oxygenated Locke solution at room temperature before being transferred to a heated perfusion chamber mounted on a Zeiss Axioskop epifluorescence microscope. Again, eGFP cells were identified using their green fluorescence and SON magnocellular neuron cell bodies were patched using infrared-DIC optics. Images were acquired using a Hamamatsu Orca-ER camera controlled by Simple PCI software (Digipixel). Patch electrodes were fabricated from borosilicate capillary tubing of 1.5 m diameter (Garner Glass Co., Claremont, CA). The pipette solution contained (in mm) 134 potassium methanesulfonate, 5 KCl, 0.1 K-EGTA, 5 Na-HEPES, 3 Mg-ATP, and 0.4 Na-GTP (pH 7.4) (4 -6 m⍀). Membrane potentials were recorded in current-clamp mode, with a patch-clamp amplifier (Axopatch 200B; Axon Instruments, Union City, CA). Recorded signals were low-pass-filtered at 1-2 kHz, digitized at 2-5 kHz with an A/D converter (Digidata 1322A; Axon Instruments) and analyzed with the pClamp software (Axon Instruments).
Calcium imaging from isolated magnocellular neurons
Magnocellular neurons from Sprague Dawley rats were enzymatically treated as described above. The tissue pieces were then rinsed with normal Locke solution and maintained in oxygenated normal Locke solution at room temperature until dissociated mechanically by gentle titration. The resulting cell suspension was gently mixed with a solution containing fura-2/AM and pluronic acid in normal Locke buffer to give a final concentration of 1 m and 0.01%, respectively. The cell suspension was then plated onto clean poly-l-lysine-treated coverslips (22 mm diameter No. 0; Merck Serono Ltd., Feltham, UK), which formed the base of heated perfusion chambers for [Ca 2ϩ ] i measurements. After 30 min at room temperature, the coverslips were gently rinsed to remove unattached cells and unincorporated dye. After another 30 min incubation at room temperature to allow deesterification of the fura-2/AM, perfusion chambers were placed on the temperature-controlled stage of an inverted microscope (Nikon Diaphot TMD) and cells were perfused with oxygenated normal Locke solution or test solutions as described below at 1 ml/min at 35 C. Cells were viewed with a ϫ40 CF fluorescence objective (numerical aperture 1.3), and putative magnocellular neurons were chosen on the basis of size (soma diameter of ϳ15 m) and morphology. The fura-2 was excited at 340 and 380 nm and emission (520 nm) detected and displayed (ImageMaster Pro software; Photon Technology International, Birmingham, NJ). Images were collected at 3 Hz, alternating between the two excitation wavelengths. Data were collected from defined regions of interest within the neurons. Fluorescence values were corrected for background and dark current, and [Ca 2ϩ ] i was calculated from the ratio between 340 and 380 nm recordings using a standard curve derived from a fura-2 Imaging Calibration Kit (Molecular Probes).
In vitro release experiments
For the in vitro release experiments, female Sprague Dawley rats (100 -150 g) were killed by decapitation, and the neurohypophysis, devoid of the pars intermedia, and both SON, were quickly removed and placed in normal Locke solution as previously described (35) . Release was measured from either individual neurohypophyses or from four SONs per chamber containing normal Locke media at 37 C. This medium was removed and replaced every 5 min for 30 -45 min before collecting any samples, to achieve stable basal levels. After this equilibration period, the media samples were retained and stored at Ϫ20 C. At time periods described below, the normal Locke solution was replaced with either a high potassium (in mm: 50 KCl, 90 NaCl, 10 HEPES, 10 glucose, 1.2 KH 2 PO 4 , 1.2 MgSO 4 , and 1.8 CaCl 2 , adjusted to pH 7.4 with NaOH and osmolarity 295-300 mOsm) solution, apelin-13 (50 nm), or a combination of apelin-13 and high K ϩ . The evoked vasopressin and oxytocin release during each period was calculated by subtracting the release under basal conditions (five times the mean of the three samples before the stimulus was applied) from that observed during, and directly after, the stimulus (a total of five fractions).
RIA
Vasopressin and oxytocin released from the explants was assayed as described before (oxytocin in Ref. 34 
Drugs and reagents
Apelin-13 was bought from Peptide Institute Inc. (Osaka, Japan) and Phoenix Pharmaceuticals (Belmont, CA). Apelin-13(F13A) was also obtained from Phoenix Pharmaceuticals. All other reagents were purchased from Sigma unless otherwise stated.
Statistical analysis
Statistical analyses were performed using SigmaStat software package (Systat Software Inc., Richmond, CA). Data were analyzed by t tests (paired or unpaired as appropriate after passed normality tests) or, when appropriate, by ANOVA followed by Student-Newman-Keuls post hoc tests. All values are expressed as mean Ϯ sem, and differences were considered significant at P Յ 0.05.
Results

APJ distribution in the SON and pituitary
Hypothalamic and pituitary sections were double labeled with immunofluorescence using antibodies against vasopressin (AVP), oxytocin (OT), or GFAP (red) and APJ (green). Confocal images showed APJ immunoreactivity in the somata, dendrites, axon fibers, and axon terminals of magnocellular vasopressin and oxytocin neurons (Fig. 1, A-D) . APJ immunoreactivity was also seen in the ventral glial lamina (Fig. 1E) and in some cells of the anterior pituitary (not shown).
In vivo electrophysiology
Experiments to determine the direct effects of apelin-13 on magnocellular neurons were carried out on eight identified vasopressin and seven oxytocin neurons. Microdialysis administration of apelin-13 onto the SON (one neuron per rat) excited all vasopressin neurons, characterized by their frequency (spikes per second) and activity quotient (calculated for the 5-min periods before and during apelin treatment). All continuously active cells were identified by their response to iv CCK (33) showing an increase in the firing rate in oxytocin (to 173 Ϯ 16.7% of control) and a decrease in the firing rate in vasopressin cells (to 76.2 Ϯ 9.17% of control, P Ͻ 0.01).
Four of the vasopressin cells were continuously active (5.54 Ϯ 1.29 spikes/sec), and four showed phasic firing patterns (activity quotient 0.68 Ϯ 0.10; intraburst firing rate 7.0 Ϯ 0.63 spikes/sec). The activity of the continuous cells rose to 7.0 Ϯ 1.15 spikes/sec (P Ͻ 0.05, Fig. 2B ) after administration of apelin-13. The activity quotient in the phasic cells increased to 0.87 Ϯ 0.07 (P Ͻ 0.05, Fig. 2C vasopressin neurons were held at Ϫ70 mV, and apelin-13 evoked a reversible inward current that lasted at least as long as apelin-13 was applied. B, Using a ramp protocol described in the inset, the whole-cell current recorded before apelin was applied (i) was subtracted from that recorded after (ii), and thus the apelin-induced current was derived (iii, gray line). The average apelin-13-induced current had a reversal potential of Ϫ32 Ϯ 2 mV (n ϭ 5). C, The apelin-13-induced current was also shown to be sensitive to Gd 3ϩ (0.1 mM, n ϭ 5), suggesting a nonspecific cation current. D, Apelin-13 did not evoke any current when applied after cells were pretreated with 0.1 mM apelin-13(F13A) (n ϭ 5). E, Apelin-13 evoked a small increase in [Ca 2ϩ ] i . in vasopressin neurons (n ϭ 12). F) Apelin-13 did not evoke an increase in [Ca 2ϩ ] i in the absence of extracellular calcium (n ϭ 5).
tended to decrease the electrical activity of oxytocin neurons that, however, did not reach statistical significance (4.47 Ϯ 1.16 spikes/sec before and 3.13 Ϯ 1.1 spikes/sec after apelin, Fig. 2, D and E) .
Because the effects of apelin-13 on vasopressin cells observed here were in contrast with a previous report using icv injection of apelin-17 in lactating rats (24), in nine experiments we administered apelin-13 icv and recorded from five continuously active and four phasic active vasopressin cells. There was no change in the activity of the continuous active vasopressin cells within the time of recording (Fig. 3, A and  C) , but a significant increase in the activity quotient of the phasic cells (from 0.52 Ϯ 0.06 to a maximum 0.86 Ϯ 0.09, P Ͻ 0.05; Fig. 3, B and D) . The intraburst firing rate did not change significantly in the phasic cells (from 9.29 Ϯ 1.45 to 9.86 Ϯ 1.91 spikes/sec) within 30 min after apelin-13 administration.
Effect of apelin on membrane potential and currents in isolated neurons and hypothalamic brain slices
The effects of apelin-13 on membrane potentials and ionic currents of SON neurons were studied by the whole-cell patch-clamp technique. Initially, studies were made using dissociated SON neurons from heterozygous GFP-vasopressin rats (27). In voltage-clamp mode, cells were held at Ϫ40 mV and stepped from Ϫ120 to Ϫ40 mV in 10-mV increments, each step over 200 msec. All GFP-positive neurons were observed to have a linear current-voltage relationship, i.e. no hyperpolarization-induced inward rectification at potentials more negative than Ϫ90 mV or a sustained outward rectification at potentials more positive than Ϫ70 mV (data not shown). This was consistent with previous studies identifying SON magnocellular neurons with a linear current-voltage relationship to express vasopressin by post hoc immunocytochemistry (37) . Twelve of 14 GFP-negative cells showed an outward rectification, indicating them to be oxytocin cells. Thus, later studies using non-GFP vasopressin rats used the presence or absence of an outward rectification in response to this protocol to identify oxytocin and vasopressin neurons, respectively.
In voltage-clamp mode, all isolated vasopressin neurons (n ϭ 10; a typical example is shown in Fig. 4A ) showed inward currents, on average 55 Ϯ 16.5 pA in amplitude in response to apelin-13 (50 nm, 3 min) when cells were clamped at Ϫ70 mV. The response to apelin-13 was rapid and lasted at least the duration of time that apelin-13 was applied, on average 5.5 Ϯ 1.5 min, and was readily reversed upon washing out (Fig. 4A) . The identity of the channels carrying the apelin-evoked inward current was investigated using ramp voltage protocols, stepping from Ϫ70 to Ϫ100 mV and then ramping up to Ϫ20 mV over 4 sec. These were applied three times before and during apelin-13 treatment. The currents used to calculate the reversal potential were those collected during the maximum evoked current. The reversal potential of the apelin-induced current was Ϫ32 Ϯ 2 (n ϭ 5, Fig.  4B ). The apelin-induced current was also completely blocked by the cation channel blocker gadolinium (Gd 3ϩ , 0.1 mm, n ϭ 5; Fig. 4C ). The peptide apelin-13(F13A) has been described as an APJspecific antagonist from its effects in vivo in blocking the hypotensive action of apelin-13 (38) . In our in vitro experiments, apelin-13(F13A) (0.1 mm) applied before (10 min) and during exposure to apelin-13 blocked the apelin-induced inward current, indicating it was also effective in vitro (n ϭ 5; Fig. 4D ).
Apelin-13 (50 nm, 3 min) stimulated a small but reproducible increase in [Ca 2ϩ ] i in 12 of 12 vasopressin neurons (Fig. 4E) . The identity of the isolated vasopressin neurons was established by their response to vasopressin (Fig. 4E ) because oxytocin neurons do not respond to vasopressin with an increase in [Ca 2ϩ ] i (39) . This increased [Ca 2ϩ ] i was absent when extracellular calcium was removed in five of five vasopressin neurons (Fig. 4F) . Because the inward current was evoked at potentials more negative than Ϫ32 mV, it is likely that the apelin-induced calcium influx occurs via the nonspecific cation channel rather The effect of applying apelin-13 (50 nM) and the APJ antagonist apelin-13(F13A) (0.1 mM) on vasopressin neurons in hypothalamic slices. A, Example of apelin-13-induced increase in action potential firing in a phasic vasopressin neuron. Apelin-13 also depolarized the neuron (the original membrane potential is indicated by the dotted line, increasing from Ϫ58 to Ϫ54 mV). B, Example showing that apelin-13(F13A) had no effect on the spontaneous action potential firing rate or pattern in a vasopressin neuron. C, The average firing rate as a percentage of a control period before exposure to apelin-13 or apelin-13(F13A) showed that apelin-13 produced a significant increase in firing rate (*, P Ͻ 0.05; n ϭ 10), whereas apelin-13(F13A) was without effect (n ϭ 10).
than a voltage-operated calcium channel. We also observed apelin-induced increases in [Ca 2ϩ ] i in oxytocin neurons (data not shown) but did not pursue this further.
The effects of apelin-13 on membrane potential and action potential firing were examined using brain slices, because vasopressin neurons in this preparation show patterns of spontaneous action potentials similar to those recorded in vivo. Cells were identified as vasopressin neurons either from a fluorescence signal or using the voltage-clamp protocol described above. Results from wild-type and vasopressineGFP rats and both genders were not different and have been pooled. In current-clamp mode, apelin-13 (50 nm) had a modest effect, depolarizing the membrane potential on average by 5.6 Ϯ 1 mV from an average resting membrane potential of Ϫ58.5 Ϯ 8.5 mV (n ϭ 10; Fig. 5A ). In both nonphasic and phasically firing neurons, apelin-13 increased the action potential firing rate (Fig. 5A) . In general, vasopressin cells did not return to pre-apelin membrane potential and firing rates until at least 10 min after perfusion of the drug was stopped. Nevertheless, cells were able to re-respond to a second apelin-13 exposure. Treatment of hypothalamic brain slices by bath perfusion with apelin-13(F13A) (0.1 mm, 15 min) was without any significant effect on spontaneous action potential firing rate or membrane potential of vasopressin neurons (n ϭ 10 neurons; Fig. 5, B and C) .
In contrast to the vasopressin neurons, all isolated neurons or cells in the hypothalamic brain slices identified as oxytocin neurons showed no increase in inward current upon exposure to apelin-13 (0.05 or 0.1 mm) or change in membrane potential or action potential firing rate.
In vitro release experiments
To test whether the effects of apelin-13 are mediated through somatodendritic or axon terminal release of vasopressin or oxytocin, we studied hormone release from isolated neural lobes and SON in vitro. The responses of vasopressin and oxytocin release from both compartments were similar after repeated stimulation with 50 mm K ϩ solution (Fig. 6 ). Apelin-13 (50 nm) given for 20 min between the two potassium stimuli significantly decreased basal vasopressin (by 78%, P Ͻ 0.05; n ϭ 6), but not oxytocin release, from the SON preparations. Release of both hormones from the neural lobe was not affected by the apelin treatment (Fig. 6 ). Apelin-13 (50 nm) also significantly inhibited 50 mm K ϩ -evoked vasopressin release from the SON explants (by 57%, P Ͻ 0.05; n ϭ 6; Fig. 7) .
In both the SON and neural lobe preparations, apelin-13 often appeared to stimulate vasopressin release within the first 5 min. However, this small increase was not statistically significant. The K ϩ -evoked release of oxytocin from the SON and vasopressin and oxytocin from the neural lobes was also not affected by apelin-13 (Fig. 7) .
Discussion
The present study demonstrated that both oxytocin and vasopressin neurons are immunoreactive for apelin receptors. Apelin-13 administration to isolated vasopressin and putative oxytocin neurons provoked an increased [Ca 2ϩ ] i in both cell types. However, apelin-13 increased the electrical activity in vivo and in vitro of vasopressin cells only. Finally, apelin-13 decreased basal and potassiumstimulated somatodendritic vasopressin release without affecting oxytocin release.
These data again show a marked dissociation between axonal and dendritic vasopressin release with a decrease in somatodendritic release but an increase in electrical activity at the cell bodies, which we anticipate would result in increased terminal secretion. However, we did not measure the contemporaneous vasopressin release from the neural lobes after apelin-13 was applied in vivo to the somata and dendrites via the microdialysis probe. This is because the apelin-13 was applied to only one of the four nuclei that project to the neural lobe, and a change in the firing rate of vasopressin neurons in one treated nucleus may not necessarily be reflected in a change in output at the neural lobe. Generally, increased action potential firing is accompanied by increased secretion. Here we show that apelin-13 increases the electrical activity of vasopressin neurons, while decreasing somatodendritic release. However, this is not the first observation that a change in action potential firing rate does not alter peptide release from magnocellular neuron somata and dendrites (35) .
That release from these two compartments can be regulated wholly independently has been previously shown (35, 40) . For example, oxytocin cells express MC4 receptors, through which ␣-MSH acts and MC4 agonists trigger intracellular calcium release in oxytocin cells, evoke dendritic release of oxytocin, and induce expression of the immediateearly gene c-fos. However, ␣-MSH inhibits the electrical activity of oxytocin neurons and so reduces the secretion of oxytocin into the blood (40) .
APJ was distributed throughout magnocellular vasopressin neurons with intensive labeling of cell bodies, dendrites, and axon terminals. APJ immunoreactivity was also seen on oxytocin cells and cells of the anterior pituitary. Labeling of vasopressin neurons is in accordance with previous in situ hybridization studies showing APJ mRNA expression in vasopressin cells that is up-regulated during osmotic stimuli (41) . Using in situ hybridization combined with immunohistochemistry, high expression of apelin mRNA in corticotrophs of the anterior pituitary has been shown, suggesting a local interaction between apelin and the release of ACTH (42) . The physiological significance of APJ expression on oxytocin neurons is currently unknown; in our experiments, apelin administration had no effect on the electrical activity of oxytocin neurons activity in vivo and in vitro or somatodendritic oxytocin release at doses that affected vasopressin cell activity and vasopressin release. Likewise, despite a strong immunocytochemical APJ signal, application of apelin-13 to neural lobe preparations had no effect on vasopressin release from axon terminals in vitro.
There was also intensive APJ staining in the ventral glia lamina. Colocalization of APJ with the glial cell marker GFAP has been reported previously (8, 43) . However, in the former paper, glial cell expression of APJ was thought to be in oligodendrocytes with limited expression in astrocytes where oligodendrocytes and astrocytes were identified by staining against galactosylceramide and GFAP, respectively. Choe and colleagues (43) reported that, despite the presence of APJ immunoreactivity, astrocytes stimulated with apelin did not show an increase in [Ca 2ϩ ] i . The functional significance of APJ expression on astrocytes remains unknown.
The literature regarding the effects of apelin in regulating vasopressin release and drinking behavior is controversial. The icv injection of apelin-13 and apelin-17 inhibited basal and dehydrationinduced release of vasopressin and water intake in mice and rats (18), suggesting an inhibitory role of apelin in the regulation of vasopressin release. However, in other studies, apelin-13 administered icv dose-dependently increased water intake in rats (5, 25) or had no effect (26).
In our in vivo preparation, apelin-13 was applied directly onto SON neurons by microdialysis administration (32), resulting in an increase in the activity quotient (phasic cells) and mean spike activity (continuous active cells) of all vasopressin cells tested. This finding is in direct contrast to the results on lactating animals recently published by others (24). The icv injection of the apelin agonist K17F induced a gradual and sustained inhibition of phasic vasopressin cells for up to 60 min after injection (24). In our study, in virgin female rats, we did not find any changes in the activity of continuous active vasopressin or oxytocin cells within 15-30 min after icv apelin-13 injection but again found a significant increase in the activity quotient of phasic active cells. These differences may be due to the physiological conditions of the animals. In the lactating rat model, vasopressin neurons are hyperactive (44) to preserve body water content and to optimize milk production. Alternatively, apelin, as vasopressin, might affect the firing pattern of vasopressin cells dependent on their ongoing electrical activity so that fast-firing neurons are slowed and slow-firing neurons are excited (45) . A direct excitatory effect of apelin on the electrical activity is supported by our in vitro findings. Apelin-induced inward currents recorded under voltage clamp suggest the activation of a non-voltage-dependent current, and the recorded reversal potential was close to the reversal potential of nonselective cation currents of SON neurons and resembles the currents obtained with other peptides such as CCK, angiotensin II, activin A, neurotensin, and PACAP (46 -49) . However, further investigation is required to determine the different ion permeability, in other words whether apelin induces an inward calcium current via a nonspecific cationic channel.
The second messenger signaling system used by APJ upon binding apelin appears to be dependent on cell type. In studies using APJ-transfected Chinese hamster ovary cells, apelin inhibits forskolin-induced cAMP production (8, 18 ), suggesting APJ is functionally linked to G␣i. Apelin can also activate kinases involved in cellular survival such as ERK-1/2 (50, 51) or AKT (52) . However, although the neuronal cell lines 293 (8, 53) and NT2 (43) respond to apelin with an increase in [Ca 2ϩ ] i , APJ-expressing Chinese hamster ovary cells do not (2, 50, 54) . Apelin evoked an increase in [Ca 2ϩ ] i in vasopressin neurons. Furthermore, apelin did not increase [Ca 2ϩ ] i in cells perfused with Ca 2ϩ -free solution, indicating that apelin induces calcium influx rather than release from intracellular stores. The consequences of apelin-induced changes in intracellular calcium concentration in magnocellular neurons are currently unknown.
The local excitatory actions of apelin on the electrical activity of vasopressin neurons may be mediated through somatodendritic vasopressin release. Vasopressin neurons discharge in a characteristic phasic pattern that optimizes the efficiency of stimulus-secretion coupling at the nerve terminals. Magnocellular neurons release large amounts of oxytocin and vasopressin from their dendrites (55) , and dendritically released vasopressin itself modulates this phasic activity by a predominantly inhibitory action (32, 45) . In vivo retrodialysis of vasopressin onto vasopressin neurons inhibited vasopressin neurons by reducing their firing rate, whereas retrodialysis of a V 1 -receptor antagonist partially reversed the effects of vasopressin (32). Functional evidence suggests that the effects of vasopressin on electrical activity are likely to be inhibitory. The icv injection of vasopressin decreases plasma vasopressin concentration (56), whereas V 1 /V 2 antagonists enhance peripheral vasopressin release in response to osmotic stimulation (57) .
To assess the effects of apelin on somatodendritic peptide vasopressin release, we used in vitro release studies from SON explants (35) demonstrating an inhibitory action of apelin on basal and stimulated somatodendritic vasopressin release. Our data imply that vasopressin and apelin are released differentially from vasopressin neurons in which they are colocalized but found in neurosecretory granules differing in size and distribution (23). Although the APJ antagonist apelin-13(F13A) blocked the exogenous apelin-13-evoked inward current, we did not observe an effect of the antagonist on membrane potential or action potential firing rate, which suggests that apelin is not being tonically released. In addition, we have not been successful in measuring potassiumstimulated apelin release from our SON explant preparation, which may be due to the low amount of apelin released and/or the detection limited of the enzyme immunoassay used (minimum sensitivity, 0.07 ng/ml; Apelin-12 Enzyme ImmunoAssay from Phoenix Pharmaceuticals).
It is tempting to speculate that inhibition of dendritic vasopressin release by apelin may remove an inhibitory tone leading to excitation of vasopressin cell activity. Osmotic challenges such as dehydration increase both the firing rate of vasopressin cells and vasopressin release (58, 59) , and in a dual immunolabeling confocal microscopy study, Reaux-Le Goazigo and colleagues (23) have shown that the number and labeling intensity of magnocellular apelin-immunoreactive cells increased significantly after dehydration, whereas the number and labeling density of vasopressinimmunoreactive neurons significantly decreased. The authors speculate that an inhibition of somatodendritic apelin release is partly responsible for the observed effect. However, this hypothesis requires further evaluation.
